Publications by authors named "Shams Nassir"
Background: Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib is an oral Janus kinase (JAK) 1/2 inhibitor that interrupts the signaling pathway of interferon gamma (IFN)-γ, a cytokine implicated in the pathogenesis of LP.
Methods: In this phase II trial, twelve patients with cutaneous LP received baricitinib 2 mg daily for 16 weeks, accompanied by in-depth spatial, single-cell, and bulk transcriptomic profiling of pre- and post-treatment samples.
Article Synopsis
- Necrobiosis lipoidica (NL) is a rare skin disease with limited treatment options, and this study aimed to evaluate the effectiveness of ruxolitinib, a Jak1/2 inhibitor, for managing NL.
- The phase 2 study involved 12 patients and found that, after 12 weeks of treatment, NL lesions significantly improved, showing a 58.2% decrease in severity.
- Additionally, genetic analysis indicated that ruxolitinib affects specific immune pathways linked to NL, although the study's small size and restricted patient criteria were notable limitations.
Background: Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib is an oral Janus kinase (JAK) 1/2 inhibitor that interrupts the signaling pathway of interferon (IFN)-γ, a cytokine implicated in the pathogenesis of LP.
Methods: In this phase II trial, twelve patients with cutaneous LP received baricitinib 2 mg daily for 16 weeks, accompanied by in-depth spatial, single-cell, and bulk transcriptomic profiling of pre-and post-treatment samples.